524790

Everest Organics financials

Market cap
₹264 Cr
Sector
Healthcare

What Everest Organics does

Everest Organics manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates at a single USFDA-approved facility in Sangareddy District, Telangana, holding close to 15% of the global prazole market. Its portfolio spans anti-ulcerants (Omeprazole, Esomeprazole, Pantoprazole, Rabeprazole, Dexlansoprazole), an anti-hyperlipidemic (Fenofibrate), an anti-fungal (Itraconazole), an anticoagulant (Rivaroxaban), an antihyperuricemic (Febuxostat) and antivirals (Oseltamivir, Remdesivir). The company also recovers and sells green by-product chemicals from its own manufacturing waste streams, and in FY24-25 expanded into contract development and manufacturing (CDMO/CMO) services for other pharma companies. Products are exported to more than 40 countries with a strong presence across South Asia.

Segments

  • APIs & Intermediates manufacturing
  • CDMO/CMO contract manufacturing
  • By-product green chemicals
Manufacturing facility
1 API plant, Sangareddy District, Telangana — 33 acres total (10 acres built-up, 23 acres green belt)
Global prazole market share
~15% of global prazole market
Export reach
40+ countries, strong presence in South Asia
Core API portfolio
9 APIs (Omeprazole, Esomeprazole, Pantoprazole, Fenofibrate, Dexlansoprazole, Rabeprazole, Itraconazole, Rivaroxaban, Febuxostat) plus antivirals Oseltamivir & Remdesivir
Regulatory certifications
cGMP, cGLP, WHO-GMP, USFDA-approved facility; ISO 9001:2015, EMS 14001:2015, OHSAS 18001:2007
By-product green chemicals recovered
10 (e.g. Ammonium Sulphate, Calcium Sulphate, Calcium Nitrate, Sodium Sulphate)
Founded 1995Headquarters Aroor Village, Sadasivapet Mandal, Medak, Telangana 502291, India Company website

Quarterly results

Q1 FY27: revenue down 10.0%, net profit down 21.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue44 42 41 54 51 +16%43 +1%49 +19%48 −10%
EBITDA3 4 3 4 5 +50%4 −12%7 +95%4 −2%
Net profit1 1 3 1 1 +57%0 −68%3 −10%1 −21%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −34.5% 1Y

₹200₹300₹400₹500Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹404.9 on 10 Sept 2025 → ₹265.15. High ₹529 (2 Jan 2026), low ₹203.45 (30 Mar 2026).

Financials, as filed

Revenue grew 2.3% a year over 3 years, FY23 to FY26. Operating margin widened to 10.1%.

Year endingFY23FY24FY25FY26
Revenue₹183 Cr₹197 Cr₹159 Cr₹196 Cr
Operating profit₹1 Cr₹11 Cr₹7 Cr₹20 Cr
Operating margin0.5%5.6%4.5%10.1%
Interest₹3 Cr₹5 Cr₹5 Cr₹7 Cr
Depreciation₹4 Cr₹6 Cr₹6 Cr₹6 Cr
Net profit₹-0 Cr₹0 Cr₹-1 Cr₹6 Cr
Net margin-0.1%0.1%-0.8%2.8%
Cash from operations₹18 Cr₹16 Cr₹-5 Cr₹4 Cr
Free cash flow₹5 Cr₹3 Cr₹-11 Cr₹2 Cr
ROCE4.0%6.0%2.0%12.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹10 Cr₹10 Cr
Reserves₹39 Cr₹39 Cr₹38 Cr₹38 Cr₹63 Cr₹66 Cr
Borrowings₹23 Cr₹39 Cr₹51 Cr₹58 Cr₹49 Cr₹50 Cr
Other liabilities₹66 Cr₹92 Cr₹105 Cr₹123 Cr₹115 Cr₹114 Cr
Total liabilities₹135 Cr₹178 Cr₹202 Cr₹227 Cr₹237 Cr₹240 Cr
Fixed assets₹44 Cr₹49 Cr₹54 Cr₹52 Cr₹49 Cr₹48 Cr
Capital work in progress₹0 Cr₹8 Cr₹12 Cr₹21 Cr₹22 Cr₹21 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹92 Cr₹121 Cr₹136 Cr₹153 Cr₹166 Cr₹171 Cr
Total assets₹135 Cr₹178 Cr₹202 Cr₹227 Cr₹237 Cr₹240 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −1.39 pp while the public added +1.39 pp. The shareholder count shrank 5% to 7,827.

Promoters
59.6%
DIIs
0.0%
Public
40.4%

Since Jun 2025

  • Promoters −1.39 pp
  • Public +1.39 pp
  • DIIs 0.00 pp

How it drifted, 12 quarters

Over this window the public went from 25.8% to 40.4% — +14.6 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 74.2%, DIIs 0.0%, Public 25.8%.Dec '23: Promoters 74.2%, DIIs 0.0%, Public 25.8%.Mar '24: Promoters 74.2%, DIIs 0.0%, Public 25.8%.Jun '24: Promoters 74.2%, DIIs 0.0%, Public 25.8%.Sep '24: Promoters 74.2%, DIIs 0.1%, Public 25.8%.Dec '24: Promoters 74.2%, DIIs 0.1%, Public 25.8%.Mar '25: Promoters 61.1%, DIIs 0.0%, Public 38.9%.Jun '25: Promoters 61.0%, DIIs 0.0%, Public 39.0%.Sep '25: Promoters 59.6%, DIIs 0.0%, Public 40.4%.Dec '25: Promoters 59.6%, DIIs 0.0%, Public 40.4%.Mar '26: Promoters 59.6%, DIIs 0.0%, Public 40.4%.Jun '26: Promoters 59.6%, DIIs 0.0%, Public 40.4%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Everest Organics above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Veerat Finance Investment Limited 38.37%unchanged
Krishna Veni Srikakarlapudi 16.01%unchanged
R Venkata Narayana 7.52%unchanged
Greenpath Energy Private Limited 7.44%−0.09 pp
Bk Advance Research Llp 2.30%unchanged
Jayant Prasad Paleti 1.32%unchanged
Nadimpalli V Raju 1.16%unchanged
Sri Kakarlapudi Sirisha 1.11%unchanged
Sai Prasanna Manchineni 1.02%unchanged
Rajagopal Rao Rangineni 0.58%unchanged
Hari Krishna Sk 0.05%unchanged
Srikakarlapudi Gowri Parvathi 0.02%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Everest Organics

Guides on how to read this kind of business and the numbers that matter.